Jack  Kaye net worth and biography

Jack Kaye Biography and Net Worth

Director of uniQure

Jack Kaye has served as a member of our Board since 2016. Mr. Kaye serves as Chair of our Audit Committee and as a member of our Compensation Committee. Mr. Kaye has served on the board of directors of Dyadic International, Inc. (OTC: DYAI) since February 2015, and on the board of directors of TDA Industries, Inc., a private company, since February 2024. At Dyadic, Mr. Kaye serves as Chair of the company’s audit committee and as a member of the compensation committee. He has also served as Chairman of the audit committee of Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) from 2006 to 2016. Mr. Kaye was a partner at Deloitte LLP from 1978 until May 2006. At Deloitte, he was responsible for servicing a diverse client base of public and private, global, and domestic companies in a variety of industries. Mr. Kaye has extensive experience consulting with clients on accounting and reporting matters, private and public debt financings, SEC rules and regulations, corporate governance, and Sarbanes-Oxley matters. Prior to retiring, Mr. Kaye served as Partner-in-Charge of Deloitte’s Tri-State Core Client practice, a position he held for more than 20 years. Mr. Kaye has a Bachelor of Business Administration from Baruch College and is a Certified Public Accountant.

What is Jack Kaye's net worth?

The estimated net worth of Jack Kaye is at least $483.59 thousand as of November 4th, 2025. Kaye owns 20,439 shares of uniQure stock worth more than $483,587 as of December 4th. This net worth approximation does not reflect any other assets that Kaye may own. Learn More about Jack Kaye's net worth.

How do I contact Jack Kaye?

The corporate mailing address for Kaye and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at investors@uniqure. Learn More on Jack Kaye's contact information.

Has Jack Kaye been buying or selling shares of uniQure?

During the past quarter, Jack Kaye has sold $1,177,495.40 in shares of uniQure stock. Most recently, Jack Kaye sold 38,810 shares of the business's stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $30.34, for a transaction totalling $1,177,495.40. Following the completion of the sale, the director now directly owns 20,439 shares of the company's stock, valued at $620,119.26. Learn More on Jack Kaye's trading history.

Who are uniQure's active insiders?

uniQure's insider roster includes Walid Abi-Saab (Insider), Madhavan Balachandran (Director), Pierre Caloz (COO), Ricardo Dolmetsch (Insider), Robert Gut (Director), Matthew Kapusta (CEO), Jack Kaye (Director), Christian Klemt (CFO), Alexander Kuta, III (VP), David Meek (Director), Leonard Post (Director), and Jeannette Potts (Insider). Learn More on uniQure's active insiders.

Are insiders buying or selling shares of uniQure?

In the last twelve months, insiders at the biotechnology company sold shares 23 times. They sold a total of 432,748 shares worth more than $13,686,033.43. The most recent insider tranaction occured on November, 6th when Director Robert Gut sold 31,434 shares worth more than $856,890.84. Insiders at uniQure own 4.8% of the company. Learn More about insider trades at uniQure.

Information on this page was last updated on 11/6/2025.

Jack Kaye Insider Trading History at uniQure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/4/2025Sell38,810$30.34$1,177,495.4020,439View SEC Filing Icon  
6/20/2025Sell2,112$14.45$30,518.4020,439View SEC Filing Icon  
1/28/2020Sell806$62.20$50,133.2014,128View SEC Filing Icon  
See Full Table

Jack Kaye Buying and Selling Activity at uniQure

This chart shows Jack Kaye's buying and selling at uniQure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

uniQure Company Overview

uniQure logo
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More

Today's Range

Now: $22.74
Low: $21.00
High: $23.98

50 Day Range

MA: $45.23
Low: $22.74
High: $70.59

2 Week Range

Now: $22.74
Low: $6.14
High: $71.50

Volume

9,092,137 shs

Average Volume

2,488,021 shs

Market Capitalization

$1.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59